# COYA (Coya Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Coya Therapeutics, Inc. reported $4.69M in revenue and a net loss of $30.17M for the trailing twelve months ended September 30, 2026 (down 93.4% year over year), with a -675.3% operating margin.

- Canonical: https://convexityos.com/fundamentals/COYA
- Markdown: https://convexityos.com/fundamentals/COYA.md
- SEC CIK: 0001835022
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:51 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001835022&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $4.69M | -93.4% YoY |
| Operating Income | TTM | -$31.67M | -675.3% margin |
| Net Income | TTM | -$30.17M | -643.5% net margin |
| Diluted EPS | TTM | -$1.29 | Split-adjusted |
| Free Cash Flow | TTM | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $35.80M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| **Revenue** | $7.95M | $3.55M | $6.00M | $0 | -- |
| Research & Development | $16.73M | $11.87M | $5.50M | $4.41M | $2.54M |
| Total Operating Expenses | $30.50M | $20.80M | $13.91M | $9.81M | $4.87M |
| **Operating Income** | -$22.56M | -$17.25M | -$7.90M | -$9.81M | -$4.87M |
| **EBITDA** | -$22.53M | -$17.22M | -$7.88M | -$9.78M | -$4.85M |
| Income Before Tax | -$21.22M | -$15.60M | -$7.26M | -$12.24M | -- |
| Income Tax Expense | $3.1K | -$720K | $724K | $0 | -- |
| **Net Income** | -$21.23M | -$14.88M | -$7.99M | -$12.24M | -$4.89M |
| Basic EPS | -$1.27 | -$0.98 | -$0.79 | -$4.73 | -$1.89 |
| **Diluted EPS** | -$1.27 | -$0.98 | -$0.79 | -$4.73 | -$1.89 |
| Basic Shares Outstanding | 16.7M | 15.2M | 10.2M | 2.6M | 2.6M |
| Diluted Shares Outstanding | 16.7M | 15.2M | 10.2M | 2.6M | 2.6M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $234K | $244K | $251K | $3.96M | $3.56M | $164K | $258K | $2.0K |
| Research & Development | $8.57M | $5.03M | $4.10M | $4.94M | $2.92M | $3.66M | $5.21M | $1.94M |
| Total Operating Expenses | $11.18M | $7.29M | $7.89M | $9.99M | $6.00M | $6.58M | $7.93M | $4.08M |
| **Operating Income** | -$10.95M | -$7.05M | -$7.64M | -$6.03M | -$2.43M | -$6.41M | -$7.68M | -$4.08M |
| **EBITDA** | -$10.95M | -$7.04M | -$7.64M | -$6.02M | -$2.43M | -$6.41M | -$7.67M | -$4.07M |
| Income Before Tax | -$10.62M | -$6.64M | -$7.21M | -$5.71M | -$2.12M | -$6.09M | -$7.31M | -- |
| Income Tax Expense | -- | -- | -- | -- | -- | $0 | -- | -- |
| **Net Income** | -$10.62M | -$6.64M | -$7.21M | -$5.71M | -$2.12M | -$6.09M | -$7.31M | -$2.92M |
| Basic EPS | -$0.45 | -$0.28 | -$0.32 | -- | -$0.13 | -$0.36 | -$0.44 | -- |
| **Diluted EPS** | -$0.45 | -$0.28 | -$0.32 | -- | -$0.13 | -$0.36 | -$0.44 | -- |
| Basic Shares Outstanding | 23.5M | 23.5M | 22.6M | -- | 16.7M | 16.7M | 16.7M | -- |
| Diluted Shares Outstanding | 23.5M | 23.5M | 22.6M | -- | 16.7M | 16.7M | 16.7M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $46.82M | $38.34M | $32.63M | $5.93M | $4.34M |
| **Cash & Short-Term Investments** | $46.82M | $38.34M | $32.63M | $5.93M | $4.34M |
| **Total Current Assets** | $49.94M | $44.31M | $41.20M | $7.18M | $4.58M |
| Property, Plant & Equipment, Net | $11K | $39K | $66K | $93K | $121K |
| **Total Non-Current Assets** | $11K | $39K | $66K | $1.21M | $208K |
| **Total Assets** | $49.95M | $44.35M | $41.26M | $8.40M | $4.79M |
| Accounts Payable | $1.06M | $1.59M | $1.16M | $1.82M | $858K |
| Deferred Revenue (Current) | $1.20M | $848K | $923K | -- | -- |
| **Total Current Liabilities** | $5.87M | $3.82M | $5.05M | $3.82M | $1.15M |
| **Total Non-Current Liabilities** | $1.05M | $945K | $575K | $12.97M | $0 |
| **Total Liabilities** | $6.92M | $4.77M | $5.63M | $16.79M | $1.15M |
| Common Stock | $2.1K | $1.7K | $1.4K | $259 | $259 |
| Retained Earnings | -$61.96M | -$40.74M | -$25.86M | -$17.87M | -$5.62M |
| **Total Stockholders' Equity** | $43.03M | $39.58M | $35.64M | -$8.39M | $3.64M |
| Total Equity | $43.03M | $39.58M | $35.64M | -$8.39M | $3.64M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $35.80M | $43.18M | $50.72M | $46.82M | $28.13M | $29.76M | $35.53M | $38.34M |
| **Cash & Short-Term Investments** | $35.80M | $43.18M | $50.72M | $46.82M | $28.13M | $29.76M | $35.53M | $38.34M |
| **Total Current Assets** | $39.07M | $47.06M | $53.26M | $49.94M | $32.02M | $33.43M | $38.37M | $44.31M |
| Property, Plant & Equipment, Net | $2.8K | $5.6K | $8.4K | $11K | $18K | $25K | $32K | $39K |
| Other Non-Current Assets | $245K | $245K | -- | -- | -- | -- | -- | -- |
| **Total Non-Current Assets** | $248K | $250K | $8.4K | $11K | $18K | $25K | $32K | $39K |
| **Total Assets** | $39.32M | $47.31M | $53.27M | $49.95M | $32.04M | $33.45M | $38.40M | $44.35M |
| Accounts Payable | $2.45M | $1.09M | $948K | $1.06M | $1.11M | $931K | $1.69M | $1.59M |
| Deferred Revenue (Current) | $1.16M | $1.23M | $1.24M | $1.20M | $917K | $731K | $841K | $848K |
| **Total Current Liabilities** | $5.39M | $3.51M | $3.55M | $5.87M | $3.67M | $4.50M | $4.34M | $3.82M |
| **Total Non-Current Liabilities** | $355K | $520K | $754K | $1.05M | $1.09M | $641K | $694K | $945K |
| **Total Liabilities** | $5.75M | $4.03M | $4.30M | $6.92M | $4.76M | $5.14M | $5.04M | $4.77M |
| Common Stock | $2.3K | $2.3K | $2.3K | $2.1K | $1.7K | $1.7K | $1.7K | $1.7K |
| Retained Earnings | -$86.43M | -$75.81M | -$69.17M | -$61.96M | -$56.25M | -$54.14M | -$48.04M | -$40.74M |
| **Total Stockholders' Equity** | $33.57M | $43.28M | $48.97M | $43.03M | $27.28M | $28.31M | $33.37M | $39.58M |
| Total Equity | $33.57M | $43.28M | $48.97M | $43.03M | $27.28M | $28.31M | $33.37M | $39.58M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Net Income | -$21.23M | -$14.88M | -$7.99M | -$12.24M | -$4.89M |
| Depreciation & Amortization | $27K | $27K | $27K | $27K | $16K |
| Stock-Based Compensation | $4.29M | $2.66M | $872K | $207K | $233K |
| Change in Payables | -$527K | $477K | $299K | $845K | $665K |
| **Operating Cash Flow** | -$10.74M | -$10.29M | -$11.19M | -$7.24M | -$3.90M |
| **Investing Cash Flow** | -$1.16M | -$25K | -$543K | -$525K | -$137K |
| Common Stock Issued | $20.35M | $14.00M | -- | -- | -- |
| **Financing Cash Flow** | $20.39M | $16.03M | $38.43M | $9.36M | -$341K |
| **Net Change in Cash** | $8.48M | $5.71M | $26.69M | $1.59M | -$4.38M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$10.62M | -$6.64M | -$7.21M | -$5.71M | -$2.12M | -$6.09M | -$7.31M | -$2.92M |
| Depreciation & Amortization | $2.8K | $2.8K | $2.8K | $6.8K | $6.8K | $6.8K | $6.8K | $6.8K |
| Stock-Based Compensation | $910K | $944K | $2.20M | $1.10M | $1.07M | $1.04M | $1.08M | $791K |
| Change in Payables | $1.49M | $59K | -$155K | -$51K | $180K | -$759K | $102K | $1.25M |
| **Operating Cash Flow** | -$7.24M | -$7.38M | -$6.21M | -$1.01M | -$1.13M | -$5.77M | -$2.83M | -$2.41M |
| **Investing Cash Flow** | -$23K | -$1.7K | -$885K | -- | -- | -- | -- | $0 |
| Common Stock Issued | $0 | -$42K | $11.00M | -- | -- | -- | -- | -- |
| **Financing Cash Flow** | -$120K | -$166K | $11.00M | $20.35M | $19K | $0 | $19K | $9.69M |
| **Net Change in Cash** | -$7.38M | -$7.54M | $3.90M | $18.69M | -$1.63M | -$5.77M | -$2.81M | $7.28M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -283.9% | -485.4% | -131.7% | -- | -- |
| **Net Profit Margin** | -267.1% | -418.7% | -133.1% | -- | -- |
| Return on Equity (ROE) | -49.3% | -37.6% | -22.4% | -- | -134.3% |
| Return on Assets (ROA) | -42.5% | -33.6% | -19.4% | -145.8% | -102.1% |
| Current Ratio | 8.50x | 11.59x | 8.15x | 1.88x | 3.99x |
| Quick Ratio | 7.97x | 10.02x | 6.46x | 1.55x | 3.78x |
| **Revenue Growth (YoY)** | +123.6% | -40.8% | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -675.3% | -288.7% | -283.6% | -283.9% | -516.7% | -5342.3% | -527.6% | -485.4% |
| **Net Profit Margin** | -643.5% | -270.2% | -266.1% | -267.1% | -462.3% | -4803.1% | -465.0% | -418.7% |
| Return on Equity (ROE) | -89.9% | -50.1% | -43.1% | -49.3% | -67.6% | -71.8% | -51.4% | -37.6% |
| Return on Assets (ROA) | -76.7% | -45.8% | -39.7% | -42.5% | -57.5% | -60.8% | -44.6% | -33.6% |
| Current Ratio | 7.24x | 13.40x | 15.02x | 8.50x | 8.73x | 7.43x | 8.84x | 11.59x |
| Quick Ratio | 6.64x | 12.29x | 14.30x | 7.97x | 7.67x | 6.61x | 8.18x | 10.02x |
| **Revenue Growth (YoY)** | -93.4% | +49.0% | -2.6% | +202768.8% | -- | -95.2% | +103.3% | -100.0% |
| Operating Income Growth (YoY) | -- | -- | -- | -- | -- | -- | -- | -324.8% |
| **Net Income Growth (YoY)** | -- | -- | -- | -- | -- | -- | -- | -330.3% |
| Operating Cash Flow Growth (YoY) | -- | -- | -- | -- | -- | -- | -231.8% | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
